7:30 AM ET
8-K
Loan & Debt
Arrowhead Pharmaceuticals $400M Debt Financing with Sixth Street Lending Partners
Arrowhead Pharmaceuticals refinanced its existing senior secured term loans by entering into a new $400 million Amended and Restated Financing Agreement with Sixth Street. The new facility significantly lowers borrowing costs from a 15% fixed rate to SOFR plus 5.50%, extends the maturity to November 2031, and eliminates previous requirements to sweep commercial revenue or milestone payments for debt repayment.
- Value
- $400M
- Counterparty
- Sixth Street Lending Partners
- Term
- 5 years